Catalogue

Background
Cytokeratin 14 (CK14) belongs to the acid subfamily of CKs (Type I) and is characteristic of stratifying epithelia (trachea, bronchi, cervix, epidermis, sweat glands). The antibody to CK14 is helpful to distinguish between stratifying epithelia and simple epithelia, which don't express this type of cytokeratins. Tumours of squamous cell origin will be stained with this antibody. Cytokeratins are a group of water-insoluble filamentous proteins. They are constituents of the cytoskeleton of epidermal cells and other epithelial cells. Up to now 20 different cytokeratins have been characterised by gel electrophoresis. They have been subdivided into a basic and an acid subfamily. Most frequently the nomenclature according to Moll et al. (1982) is used. Human cytokeratin 14.

Source

Immunogen: C-terminal 15-AA peptide of cytokeratin 14 conjugated to thyroglobulin

Product
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).

Concentration: 40 µg/ml

Specificity

Species Reactivity: Human

Applications
IHC(C, P)

Incubation Time: 60 min at RT

Working Concentration: (liquid conc.) 1:20-1:50

Pre-Treatment: Heat pre-treatment of formalin-fixed tissue with Unmasking Fluid G (Art. No. DE007)

Positive Control: Bronchial epithelium

Storage
2-8°C

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
1. Moll R., Franke W.W., Schiller D.L., Geiger B., and Krepler R. (1982) The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells. Cell 31; 11 ff. 2. Sun T.-T. Tseng S.C.G., Huang A.J.W., Cooper D., Lynch M.H., Weiss R., Eichner R., and Schermer (1985) Monoclonal antibody studies of keratin expression: A review. In: Intermediate Filaments , Wang E. et al. eds. N.Y. Acad. Sci. 455, pp 307 ff. 3. Harnden P. and Southgate J. (1997) Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol. 50(12):1032-1033. 4. Sarbia M, Verreet P, Bittinger F, Dutkowski P, Heep H, Willers R, Gabbert HE. (1997) Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 79(10):1871-1878. 5. Lakhani S.R., O'Hare M.J., Monaghan P., Winehouse J., Gazet J.C., Sloane J.P. (1995) Malignant myoepithelioma (myoepithelial carcinoma) of the breast: a detailed cytokeratin study. J. Clin. Pathol. 48(2):164-167.

Safety Datasheet(s) for this product: